Martin Šmakal
0000-0002-5618-5986
Publication & Citation Trends
Publications
0 total
OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer
Cited by 0
Semantic Scholar
Anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with metastatic castration-resistant prostate cancer.
Cited by 0
Semantic Scholar
Liver adenomatosis mimics metastatic liver involvement on FDG-PET/ CT. OA
Cited by 0
Semantic Scholar
Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors.
Cited by 0
Semantic Scholar
265P Phase II study of DHP107 oral paclitaxel compared to IV paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer (MBC): Opera (NCT03326102) OA
Cited by 2
Semantic Scholar
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida) OA
Cited by 64
Semantic Scholar
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin alfa for Chemotherapy-Induced Anemia in Patients With Advanced Non-Small Cell Lung Cancer. OA
Cited by 14
Semantic Scholar
Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy OA
Cited by 9
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(11)
Lung Cancer Treatments and Mutations
(10)
Erythropoietin and Anemia Treatment
(6)
Cancer Treatment and Pharmacology
(6)
Lung Cancer Research Studies
(6)
Affiliations
Wilhelminen Hospital
Marqués de Valdecilla University Hospital
Clinique de Genolier
INTOS (Czechia)
Johnson & Johnson (United Kingdom)